Product Images Aripiprazole

This text provides information about a prescription medication. The medication is a 5mg tablet, with a quantity of 30 tablets. It includes the NDC number, expiration date, source NDC, manufacturer's information, storage instructions, and details about repackaging. The information advises to keep the medication out of the reach of children and refers to the package insert for directions on use.*

This text provides information on the effect of different drugs on Aripiprazole, including their impact on Aripiprazole's fold change and 90% confidence interval. The drugs mentioned include CYP3A4 inhibitor Ketoconazole, CYP2D6 inhibitor Quinidine, CYP3A4 inducer Carbamazepine, Gastric acid blocker Famotidine, and others like Valproate and Lorazepam. The text shows changes relative to a reference point without the interacting drug.*

This text contains information about the effect of certain drugs on Aripiprazole, particularly focusing on the inhibitors and inducers of specific enzymes like CYP3A4, CYP2D6, and CYP3A. Additionally, it mentions the influence of different drugs such as ketoconazole, quinidine, carbamazepine, famotidine, valproate, and lorazepam on the pharmacokinetics of Aripiprazole, as shown through parameters like AUC and Cmax. The text also includes a chart displaying Dehydro-Aripiprazole Fold Change and 90% CI relative to the reference (without interacting drug).*

The text mentions the "Effect of Aripiprazole on Other Drugs" and lists various drugs showing their fold change and 90% CI in reference to a specific drug without interacting drug. The table seems to contain information on how Aripiprazole affects the pharmacokinetics of different medications.*

This text shows a Kaplan-Meier estimation of the cumulative proportion of patients with relapse in a schizophrenia study comparing Aripiprazole to a placebo. The graph displays the proportion of relapse over time, with data points for Aripiprazole and Placebo. The number of subjects at risk is listed for both treatment groups at various time points. The study duration ranges from 0 to 182 days from randomization.*

This chart displays the least-squares mean change in YGTSS Total TIC Score over the course of treatment with Aripiprazole (low and high doses) compared to placebo. The data is recorded for different weeks of treatment, providing insights into the effectiveness of Aripiprazole in managing the Total TIC Score in individuals.*